GSK and its heritage companies have been committed to advancing knowledge in the field of oncology for more than 60 years. From the decades-long partnership of Nobel laureates Gertrude Elion and Dr. George Hitchings, whose work led to the development of medicines that block nucleic acid synthesis in cancer cells, to the discovery, development and introduction of the first oral, targeted therapy for HER2 positive breast cancer, our research has resulted in new therapeutics to improve the lives of cancer patients.

Our commitment is clear: bring new medicines that will make a difference in patients’ lives. GSK continues exploring potential new cancer treatments, and has had four new medicines for the prevention or treatment of cancer approved for patients in the US in the last four years – the most of any company in the industry.

We believe it’s critical that life-saving medicines are available for patients who can benefit from them. In 2010, we launched CARES by GSK™,a simpler entryway to reimbursement for and access to GSK’s oncology and specialty medicines. GSK’s commitment to patient access is exemplified by the more than 450,000 patients who received GSK medicines through our US patient assistance programs in 2009. Information on all of GSK’s patient assistance programs can be found at www.gskforyou.com.

We are researchers, doctors, nurses, survivors and loved ones of those with cancer. We are honored to Stand Up to Cancer™ with you and look forward to more days when new breakthroughs bring hope against these serious diseases.

For more information on GSK, visit www.gsk.com.